CVS To Pull Curaleaf Products From CBD Offerings After FDA Warning; Marijuana Stocks Fall
Marijuana Industry News July 24, 2019 MJ Shareholders 0
CVS Health (CVS) said it would pull some products made by U.S. cannabis producer Curaleaf (CURLF) after the marijuana and hemp company received a warning letter from the Food and Drug Administration that said several of its hemp-based CBD products are “unapproved new drugs” that ran afoul of regulations.
About The Author:
AggregatedNews
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
No comments so far.
Be first to leave comment below.